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RNA Polymerase IIThe four members of the albumin gene family encode the serum transport proteins albumin, α-fetoprotein,
α-albumin, and vitamin D-binding protein. These genes are transcribed primarily in the liver with each
having a different pattern of developmental expression. The tight linkage of these genes, particularly that of
albumin, α-fetoprotein and α-albumin, and their liver-speciﬁc expression, has led to the suggestion that
these genes share common regulatory elements. To directly examine whether the α-fetoprotein enhancer
region could regulate the albumin gene family, expression of these genes was monitored in mice in which
this region was deleted by homologous recombination. Our data indicate that this enhancer region is
required for α-fetoprotein and albumin activation early in liver development and α-fetoprotein reactivation
during liver regeneration, but that albumin, α-albumin, and vitamin D-binding protein expression later in
hepatic development is not affected by the absence of these enhancers. We also demonstrate that RNA
polymerase II loading on the α-fetoprotein and albumin promoters is reduced in the absence of this
enhancer region, indicating a direct role for these enhancers in the assembly of the RNA Polymerase II
complex during liver development.
© 2009 Elsevier Inc. All rights reserved.Introduction
The albumin, α-fetoprotein (AFP), α-albumin (afamin; AFM) and
vitamin D-binding protein (DBP) genes comprise a small gene family
(ALB gene family) with a highly conserved intron/exon organization
that encodes proteins with similar structural and functional
properties (Belanger et al., 1994; Cooke and David, 1985; Lichen-
stein et al., 1994; Tilghman, 1985; Yang et al., 1985). Through
evolution, a series of duplications formed the genes within the ALB
family, with DBP being the most distantly related (Gibbs et al.,
1998; Haeﬂiger et al., 1989). All four genes are expressed primarily
in the liver with different patterns of developmental regulation
(Belanger et al., 1994). AFP expression is low in the foregut
endoderm and dramatically increases in progenitor hepatoblasts
that differentiate from this tissue; albumin is highly induced in
parallel with AFP in these progenitor hepatoblasts that form the
liver bud (Gauldi et al., 1996; Tilghman and Belayew, 1982). Both
AFP and albumin continue to be expressed at high levels in the fetal
liver. AFP is also abundantly expressed in the visceral endoderm ofy, Immunology and Molecular
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ll rights reserved.the yolk sac; albumin is expressed at low levels in this extraem-
bryonic tissue (Tilghman, 1985). DBP expression initiates mid-
gestation in the fetal liver (Song et al., 1998a). After birth, AFP
transcription is rapidly repressed to barely detectable levels while
albumin and DBP transcription increase slightly. Temporal activation
of AFM parallels AFP silencing during the perinatal period. Albumin,
AFM and DBP continue to be expressed in the adult liver. AFP is
normally silent after birth, but can be reactivated during periods of
liver regeneration and in hepatocellular carcinomas (Abelev, 1971;
Belanger et al., 1994; Belayew and Tilghman, 1982; Tilghman and
Belayew, 1982).
Albumin, AFP and AFM are tandemly arranged in the same
transcriptional orientation in all mammals examined, including
humans and rodents, with albumin being ∼14 kilobases (kb)
upstream of the 5′ end of AFP and AFM being 10–25 kb downstream
of the 3′ end of AFP (Belanger et al., 1994; Chevrette et al., 1987;
Ingram et al., 1981; Nishio et al., 1996; Urano et al., 1984) (Fig. 1A).
The more distantly related DBP is linked, albeit less tightly, to the
other three genes (Buetow et al., 1991); in humans and mice, DBP is
1.5 and 1.0 Mb upstream of the 5′ end of albumin, respectively, and in
the opposite transcriptional orientation (Song et al., 1999).
Several enhancers have been identiﬁed that are required for
tissue-speciﬁc expression of genes within this locus in mice. These
include the albumin enhancer, which lies ∼10 kb upstream of the
albumin gene and is able to direct high-level transgene expression in
Fig. 1. Targeting vector for deleting the AFP enhancer region. (A) Map of the albumin gene family locus. The DBP, albumin (ALB), AFP and AFM genes are designated as boxes (black
lines represent exons) with arrows representing transcription start sites. The numbers above the intergenic regions represent the distance between genes. Black ovals between the
DBP and albumin, and albumin and AFP genes represent the albumin enhancer and the three AFP enhancers, respectively. (B) Strategy for deleting the three AFP enhancers. The
uppermost structure represents the 3′ end of the albumin gene, albumin-AFP intergenic region, and 5′ end of the AFP gene. The location of cleavage sites for the restriction enzymes
ApaI (A) BglII (B), EcoRI (R), HindIII (H), and SphI (S) are shown, distances (in kb) are from the site of AFP transcription initiation. Hatched boxes labeled “A” and “B” represent
probes used for Southern analysis used to screen primary and secondary targeting events, respectively; distances between diagnostic EcoRI and HindIII sites are indicated. The next
structure is the targeting vector comprised of the 5. 8 kb AFP 5′ homologous region (from BglII site at −12.6 to ApaI site at −6.8), Neo-TK selection cassette ﬂanked by loxP sites
(gray arrows; with a HindIII site at the end of the 3′ loxP site), 4. 5 kb AFP 3′ homologous region (from SphI site at−2.0 to EcoRI site at +2.5), and the DT-A chain gene. The next two
structures represent the targeted locus before and after transient transfection with Cre recombinase, which removes the Neo-TK cassette and leaves behind a single loxP site;
distances between diagnostic EcoRI and HindIII sites for the primary and secondary ES cell clones are shown.
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Postic and Magnuson, 2000), and three AFP enhancers, E1, E2 and E3,
which are locatedwithin the albumin-AFP intergenic region (Godbout
et al., 1986, 1988)(Fig. 1A). In transgenic animals, each AFP enhancer
is sufﬁcient to activate transgenes in the yolk sac, fetal liver and gut
and continues to be active in the adult liver and gut (Camper and
Tilghman, 1989; Hammer et al., 1987; Ramesh et al., 1995). In contrast
to rodents, the human genome contains E2 and E3 but does not have
an E1 (Long et al., 2004). Enhancers for AFM have not yet been
identiﬁed, whereas multiple enhancers that govern DBP expression
have been well characterized (Hiroki et al., 2007, 2006; Song et al.,
1998b).
The tight linkage of albumin and AFP has led to the hypothesis that
both genes require the AFP enhancers for proper activation during
hepatogenesis (Godbout et al., 1986, 1988; Spear, 1999). This
possibility is supported by the fact that the albumin enhancer
exhibits only weak activity in the fetal liver (Postic and Magnuson,
2000). Furthermore, it has been suggested that a competition
between the AFP and AFM promoters for the AFP enhancers might
be responsible for the concomitant AFP repression and AFM
activation in the perinatal liver (Belanger et al., 1994; Wu et al.,
2000); consistent with this possibility, AFM levels decrease in
hepatocellular carcinomas in which AFP is activated (Wu et al.,
2000). The linkage of DBP with these other genes might also suggest
shared regulation, although studies indicate that DBP is regulated
independently of the other members of this gene family. To directly
examine whether the AFP enhancer region acts as a Locus Control
Region (LCR) and activate multiple genes within this locus,
expression of these genes was monitored in mice in which the AFP
enhancers were deleted by homologous recombination. Our dataindicate that the AFP enhancer region is required for AFP and albumin
activation early in liver development and for signiﬁcant AFP
expression at all times, including liver regeneration. However, hepatic
albumin, AFM and DBP expression later in fetal development is not
affected by the absence of these enhancers. We also demonstrate that
RNA polymerase II (RNA Pol II) loading on the AFP and albumin
promoters is decreased in the absence of the AFP enhancers,
indicating a direct role for these enhancers in assembling the RNA
Pol II complex during development.
Materials and methods
Targeting vector, ES cells, and production of chimeric mice
A BAC clone containing the AFP gene from a 129/Sv genomic BAC
library (Research Genetics) was used to obtain AFP fragments for
constructing the AFP enhancer targeting construct. A 4.8-kb region
from an ApaI site at -6,643 to a SphI site at -1,880 (relative to the AFP
transcription start site) containing the three AFP enhancers was
replaced with a ﬂoxed Neo/TK cassette (details regarding the
targeting vector will be provided upon request). The targeting vector
was electroporated into R1 ES cells and Southern analysis was used to
screen for correctly targeted clones. The Neo/TK cassette was
subsequently removed by transient transfection of Cre recombinase.
Chimeric mice were generated by aggregation of targeted R1 cells
with CD1 blastocysts, followed by mating to obtain germ-line
transmission of the targeted allele. For mouse genotyping, the primer
set for the wild type (enh+) allele is: 5′ GAATAGTCAAGGGTAGAGCC
and 5′CCACATGACTTTGTGTGAGG, which will generate a 220 bp
fragment; the primer set for the knock-out (enh−) allele is 5′
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which will generate a 450 bp fragment.
RNA isolation and analysis
Total RNA was isolated from embryonic day 14.5 (e14.5) livers or
yolk sac using Trizol followingmanufacturer's instruction (Invitrogen,
Inc). One μg of total RNA was used for reverse transcription to cDNA
using the iScript cDNA synthesis kit (Invitrogen, Inc) in a 20 μl
reaction volume. After RT, cDNA was dilute in sterile water to 100 μl.
Real time PCR was carried out using a MyIQ real time PCR detection
system (Bio-Rad Laboratories), using 1 μl of cDNA, 12. 5 μl of
Sybergreen Mix (Bio-Rad) and 5 μM of each primer in a 25 μl volume.
Each sample was analyzed in triplicate. For each run, ampliﬁcations
with water alone was a control to monitor for contamination. The
following primers were used for real-time RT-PCR: AFP, 5′AGCGAG-
GAG AAATGGTCCGG and 5′GGACATCTTCACCATGTGG; albumin, 5′
TCCTGATTGCCTTTTCCCAGTATCT and 5′GCCAGTTCACCATAGTTT
TCACGGA; AFM, 5′TTTCCTGTTGCCTTTGACTGAATCC and 5′TGACTTT-
CACCAGCGTTTCCACC; DBP, 5′GAGTGCTGTCAAGAAAACACACCCA and
5′TGCTGAGGAACACTTCTGGAACTTG; TTR, 5′GGTCAAAGTCCTG-
GATGCTGTCCGA and 5′TCATCTGTGGTGAGCCCGTGC.
For liver regeneration, adultmice (4–6weeks of age)were injected
i.p. with 50 μl of a 10% (v:v) solution of carbon tetrachloride (CCl4)
dissolved in mineral oil; control mice were injected with 50 μl of
mineral oil alone. After 3 days, livers were removed and RNA was
prepared using the lithium chloride procedure (Spear, 1994). cDNA
was prepared as described above, and standard PCR was performed;
products were resolved on polyacrylamide gels and visualized by
ethidium bromide staining. The following primer pairs were used for
RT-PCR: AFP, 5′GGACATCTTCACCATGTGG and 5′AGCGAGGA-
GAAATGGTCCGG; H19, 5′ CGTTCTGAATCAAGAAGATGCTGC and 5′
TTTGAGTCTCTCAAGCAAGGAAGG; β-actin, 5′GTGGGCCGCTCTAGG-
CACCA and 5′CGTACTCCTGCTTGCTGATCCAC.
Chromatin immunoprecipitation (ChIP) assays
Livers were removed from e14.5 embryos and snap frozen in liquid
nitrogen. After PCR genotyping, enh+/+ and enh−/− liverswere pooled
so that eachgroup contained 0.5 to 0. 7 g of tissue (from4 to 6 embryos).
Sampleswere prepared for ChIP analysis essentially as described (Wells
and Farnham, 2002). Immunoprecipitations were performed with a
rabbit anti-serum against RNA Polymerase II (N-20, Santa Cruz
Biotechnology); normal rabbit serumwasused as a control. Precipitated
DNA was analyzed using the MyIQ PCR detection system using the
following primers: AFP promoter, 5′CAAGTGACCCCTGCTCTGTTAAT and
5′TCCTGCTGAAGTCCTTTTATATCC; albumin promoter, 5′GCAAACA-
TACGCAAGGGA and 5′CAGAAAGACTCGCTCTAATATAC; TTR promoter,
5′ AGCGAGTGTTCCGATACTC and 5′ACCCCCTCCTTCCAACCCA.
Whole mount RNA in situ hybridization
Day e10.5 embryos were removed from enh+/− females that had
beenmated to enh+/−males. Genotyping of yolk sac DNAwas used to
identify enh+/+ and enh−/− embryos. For the albuminprobe, a 650 bp
HindIII fragment from a mouse albumin cDNA (Kioussis et al., 1981)
was subcloned into pBluescript. The retinol binding protein (RBP)
probe was provided by Dr. Steven Duncan (Medical College of
Wisconsin, Milwaukee,WI). For AFP, a 315 bp fragment was ampliﬁed
from fetal liver cDNA using the primers 5′CAGGGCAAAGCCCTACA-
GACC and 5′GGACATCTTCACCATGTGG and cloned into pGEMT-Easy
(Promega Corp.). Probes were generated by in vitro transcription of
linearized plasmids in the presence of digoxigenin-UTP and used for
in situ hybridization as described (Lee et al., 2005). Sense and
antisense probes were generated for each transcript. With all three
probes, NBT/BCIP incubations were carried out for 2 h.Results
Production of AFP enhancer-deﬁcient mice
The three AFP enhancers located within the albumin-AFP inter-
genic region have been identiﬁed and extensively characterized using
in vitro cell transfections and transgenicmice. To determine the role of
these enhancers during liver development within their native
chromosomal context, the enhancer region was deleted in ES cells
using homologous recombination (Fig. 1). A 4. 8 kb region encom-
passing the three enhancers was replaced with a ﬂoxed Neo-TK
cassette. Three of ninety-six clones that were screened by Southern
blot using fragment “A” as a probe (Fig. 1) exhibited correct targeting
based on the presence of a 13. 2 kb band after digestion with EcoRI
(data not shown). These primary clones were expanded and
transiently transfected with a Cre recombinase expression vector,
followed by gancyclovir selection; Southern analysis using fragment
“B” as a probe (Fig. 1) indicated that all secondary resistant clones had
deleted the Neo-TK cassette, leaving behind a single loxP site, based on
the presence of a 1 kb band after digestion with HindIII (data not
shown).
Targeted ES cells were aggregated with CD1 embryos, and the
aggregates were transferred into pseudopregnant females. The most
extensively chimeric pups (as judged by coat color and PCR/Southern
analysis of tail biopsy DNA) were bred to wild-type C3H females and
germ-line transmission of the enhancer-deleted allele (enh−) was
achieved. These offspring were used to establish a colony of enh+/−
mice. Brother-sister matings of enh+/− mice were used to obtain
enh−/− offspring. The frequency of enh+/+, enh+/−, and enh−/−
mice from these matings was essentially 1:2:1, indicating that the
absence of the AFP enhancer region did not result in embryonic
lethality.
Expression of ALB family genes in e14.5 liver and yolk sac
Wemonitored expression of genes in the ALB family at embryonic
day 14.5 (e14.5). At this mid-gestational time, the liver is still
undergoing rapid proliferation and is a mixture of hepatic and
hematopoietic cells. The albumin and AFP genes are actively
transcribed at this time, whereas this is prior to maximal AFM and
DBP expression. The livers and yolk sac were removed from embryos
derived from the mating of enh+/− parents; genotyping was
performed with tail DNA to identify enh+/+ and enh−/− embryos.
RNA was prepared and albumin, AFP, AFM, and DBP levels were
analyzed by real-time RT-PCR. We chose to use transthyretin (TTR) to
control for variations in RNA. TTR is highly expressed in fetal
hepatocytes and yolk sac, but is unlinked to the ALB gene family and
therefore would not be inﬂuenced by the presence or absence of the
AFP enhancers. Since the e14.5 liver is comprised of a variety of
hepatic and non-hepatic cell types, with a possible variability in the
cellular composition between animals, a hepatocyte-speciﬁc control
would be more appropriate than one that was expressed in all cell
types. The absence of the AFP enhancers resulted in a dramatic 12-fold
reduction of steady-state AFP mRNA levels in the fetal liver (Fig. 2A).
We also saw amodest, ∼30% reduction in albumin expression, but this
change was not statistically signiﬁcant. We also analyzed AFM and
DBP expression in e14.5 livers. As expected, both genes were
expressed at lower levels than AFP and albumin at this timepoint
although mRNA from both genes could be detected (Fig. 2B). Even
though both showed a modest reduction in expression in the absence
of the AFP enhancer region, these changes were not signiﬁcant. AFM
and DBP levels in enh+/+ and enh−/−mice in e18.5 livers, when both
genes are expressed at higher levels, also were not signiﬁcantly
different (data not shown). The second major site of AFP synthesis
during development is the extraembryonic yolk sac. Here, we saw a
signiﬁcant, 4-fold decrease in AFP expression in the absence of the AFP
Fig. 2. Analysis of ALB family gene expression in e14.5 liver and yolk sac in the presence
and absence of the AFP enhancer region. RNA was prepared from the livers and yolk sac
of embryonic day 14.5 enh+/+ (gray columns) and enh−/− (cross-hatched columns)
embryos that were obtained from the matings of enh+/−mice. Real-time PCR was used
to examine the expression of AFP and albumin in the liver and yolk sac (panel A) and
AFM and DBP in the liver (panel B). The mRNA levels were normalized to transthyretin
(TTR) mRNA levels, which is expressed in both the fetal liver and yolk sac. Each data
point represents analysis of tissues from at least 9 mice. Error bars represent standard
deviation; ⁎pb0.05.
Fig. 3. Chromatin immunoprecipitation analysis of RNAPolymerase II loading on theAFP
and albumin promoters in enh+/+ and enh−/−mice. (A) Chromatin was isolated from
the livers of enh+/+ and enh−/− e14.5 embryos and immunoprecipitated with control
Ig antiserum (not shown) or with anti-RNA Pol II. The DNA was ampliﬁed by real-time
PCR using primers for the promoters of the AFP, albumin (ALB) and transthyretin (TTR)
genes. For each of the six anti-RNA Pol II precipitations, the amount of DNA precipitated
shown is relative to the control Ig, which was arbitrarily set at 1. These data are from
pooled embryos in a single experiment and is representative of three independent
experiments; each real-time PCR reaction performed in triplicate. (B) Quantitation of
the fold difference in RNA Pol II loading on the AFP and albumin promoters in enh+/+
and enh−/− mice. This represents data compiled from three independent experiments
with different litters, and indicates that there is a roughly 4-fold and 2.5-fold decrease in
RNA Pol II loading on the AFP and albumin promoters, respectively.
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expression but this increase was not statistically signiﬁcant.
RNA pol II binding to the AFP and albumin promoters in enh+/+ and
enh−/− livers
The mechanism by which enhancers inﬂuence the developmental
control of promoter activation is not fully understood. Enhancer-
bound factors can directly or indirectly inﬂuence the binding and
assembly of factors on promoters and inﬂuence chromatin structure.
Evidence for direct interactions between enhancers and promoters
has come from chromosome conformation capture (3C) assays, which
demonstrate physical association of these elements (Carter et al.,
2002; Dekker, 2003; Tolhuis et al., 2002). We investigated whether
the AFP enhancer region could affect RNA pol II binding to the AFP and
albumin promoters. Chromatin immunoprecipitation (ChIP) analysis
was performed using antibodies against the RNA Polymerase II large
subunit with formaldehyde-ﬁxed nuclei from e14.5 enh+/+ and
enh−/− livers; as controls, ChIP was carried out with non-speciﬁc Ig.
The precipitated DNA was ampliﬁed with primers for the albumin,
AFP and TTR promoters and analyzed by real-time PCR (Fig. 3A.).
Binding of RNA Pol II was readily detected on all promoters. In the
absence of the AFP enhancers, RNA Pol II binding to the AFP andalbumin promoters was reduced. In contrast, RNA Pol II binding to
the TTR promoter was essentially the same in enh+/+ and enh−/−
mice. Compilation of data from three independent experiments
indicated that RNA Pol II binding to the AFP and albumin promoters
was reduced roughly 4-fold and 2.5-fold, respectively (Fig. 3B),
indicating that the AFP enhancer region does affect RNA Pol II
binding to both of these promoters in the fetal liver.
AFP and albumin expression in e10.5 livers
Although albumin mRNA levels were not signiﬁcantly different
between enh+/+ and enh−/− livers at e14.5, ChIP analysis suggested
that the AFP enhancer region could inﬂuence RNA Pol II binding at the
albumin promoter. This led us to consider whether a more dramatic
affect on albumin expression would be observed at an earlier
developmental timepoint. To test this possibility, we analyzed
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embryos, a time when the liver bud is easily visualized. We also
analyzed AFPmRNA levels, which should be reduced in the absence of
the AFP enhancers, and retinol binding protein (RBP), which is highly
expressed in the fetal liver and should not be inﬂuenced by the
presence or absence of the AFP enhancer region. Embryos were
removed from pregnant enh+/− mice that were mated to enh+/−
males, and yolk sac DNA was used for genotyping. As expected, RBP
transcripts were readily detected in enh+/+ and enh−/− embryos
(Fig. 4). In contrast, AFP mRNA was abundant in the liver bud of
enh+/+ embryos but not detected in the enh−/− embryos.
Strikingly, albumin expression was nearly identical to AFP in that
transcripts were present in enh+/+ embryos but were dramatically
reduced in the enh−/− liver bud. Sense probes for RBP and AFP
showed no hybridization to embryos, whereas some hybridization
was seen with the albumin sense strand probe to ectodermal regions
in the head. These data provide strong evidence that the AFP enhancer
region is required for proper activation of both the AFP and albumin
genes early in hepatogenesis.
AFP expression in adult regenerating liver
The normally silent AFP gene in the adult liver is reactivated during
liver regeneration in response to liver damage and partial hepatec-
tomy. To test whether the AFP enhancer region is required for AFP re-
expression in the adult liver, enh+/+ and enh−/− adult mice were
treated with carbon tetrachloride (CCl4) dissolved in mineral oil;
control mice were injected with mineral oil alone. CCl4 is an acute
hepatotoxin that speciﬁcally kills hepatocytes in pericentral regions of
the liver lobule. AFP expression increases transiently during the
period of regeneration subsequent to liver damage, with peak
expression seen 3 days after treatment. Low but detectable levels ofFig. 4. Whole mount RNA in situ analysis of gene expression in enh+/+ and enh−/−
embryos. Day e10.5 embryos were isolated, ﬁxed, and prepared for in situ hybridization
with digoxygenin-labeled RNA probes. Sense and antisense probes were used for
retinol binding protein (RBP, top panel), AFP (middle panel) and albumin (ALB; lower
panel). At least 4-5 embryos were hybridized with each probe; data is shown for a
single representative embryo. Magniﬁcation: 30×.
Fig. 5. AFP expression in regenerating liver of enh+/+ and enh−/−mice. Six-week-old
mice were injected intraperitoneally with 50 μl of mineral oil (MO) or 50 μl of a 10%
solution (v:v) of carbon tetrachloride in mineral oil (CCl4). Three days later, animals
were sacriﬁced and liver RNA was prepared for RT-PCR analysis. (A) Analysis of AFP,
H19 and Analysis of AFP, H19 and β-actin levels in adult liver samples. Each lane
represents analysis of a single mouse. Lanes 14, enh+/+ mice with MO; lanes 5-8,
enh+/+ mice with CCl4; lanes 9-12, enh−/− mice with MO; lanes 13-16, enh−/− mice
with CCl4. m=marker lane. (B) AFP and H19 mRNA levels Enh+/+ and Enh−/− mice
treated with MO or CCl4 were quantitated relative to β-actin mRNA levels by
densitometric analysis of the data shown in panel A.AFP were present in adult livers of wild-type mice (Fig. 5A). As
expected, AFP expression was increased in wild-type livers roughly 6-
fold after CCl4 treatment (Fig. 5B). In contrast, AFP levels in control
enh−/− adult livers were lower than in enh+/+ livers, demonstrating
that these enhancers continue to function in the adult liver for basal
AFP expression; these data are consistent with previous studies
indicating that the AFP enhancers continue to be active in the adult
liver (Ramesh et al., 1995). However, AFP levels did not increase in the
livers of adult enh−/− mice, indicating that these enhancers are
involved in AFP reactivation during regeneration. Expression of H19, a
gene unlinked to AFP that is also reactivated during liver regeneration,
increased in both enh+/+ and enh−/− mice, demonstrating that
transcriptional changes associated with regeneration were occurring
in both groups of mice (Fig. 5). These data indicate that the AFP
enhancer region is also required for reactivation of the AFP gene in
regenerating adult liver.
Discussion
The tight linkage throughout mammalian evolution, liver-enriched
expression and overlapping developmental expression proﬁles of the
ALB gene family has led to the idea that this locus may contain one or
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deletion approach to directly test whether the absence of the AFP
enhancers affected the expression of ALB family genes. Our data
indicate that the AFP enhancer region is required for normal AFP
expression in the yolk sac, fetal liver, and regenerating adult liver. Our
data also demonstrate that the AFP enhancer region is required for
albumin activation early during liver development. However, while
delayed, albumin expression does eventually reach normal levels.
Action of the albumin enhancer presumably is responsible for this
activation later in gestation. AFM expression was normal in enh−/−
mice, demonstrating that activation of this gene occurred indepen-
dently of the AFP enhancers. While these data do not rule out the
possibility of coordinated AFP repression and AFM activation during
the perinatal period, we can conclude that the AFP enhancers are not
involved in such control if it does exist.
Previous studies have identiﬁed each of the three AFP enhancers as
distinct ∼300 bp elements in the 4. 8 kb region that was deleted in the
enh−/− mice. It is possible that regulatory elements other than the
three known enhancers are present in the deleted region, and that the
loss of these elements contribute to the changes in AFP and albumin
expression. However, we believe this is unlikely. Extensive deletion
analysis of this region from the mouse and rat AFP gene in both
transgenic mice and tissue culture cells failed to identify regulatory
elements other than the known enhancers (Godbout et al., 1986;
Godbout et al., 1988; Hammer et al., 1987; Millonig et al., 1995; Wen
et al., 1991). Thus, we are conﬁdent that the changes in AFP and Alb
expression are due to the speciﬁc loss of the three AFP enhancers.
Eukaryotic genes with common evolutionary origins and related
functions are often organized into multigene loci in which genes can
be coordinately regulated during development by virtue of shared cis-
regulatory elements such as locus control regions (LCR). Multigene
loci exhibiting this type of control include those for the β-globin,
growth hormone, MHC class II and TH2 cytokines (Greaves et al., 1989;
Grosveld et al., 1987; Ho et al., 2002; Masternak et al., 1998). A
hallmark of LCRs is their hypersensitivity to cleavage with DNase I.
Previous studies by Godbout and Tilghman (1988) demonstrated that
the AFP enhancers, particularly enhancer E2, were highly sensitive to
DNase I digestion in the fetal and adult liver. These data are consistent
with the AFP enhancers acting as an LCR for genes in this region.
However, while AFP expression is dramatically reduced in the fetal
and regenerating adult liver when the AFP enhancer region is deleted,
albumin expression in the liver does reach normal levels after a delay
in activation. Furthermore, AFM mRNA levels are not affected by the
absence of the AFP enhancers. Taken together, these data indicate that
the AFP enhancer region does not function as an LCR for this locus,
althoughwe cannot rule out the possibility of an LCR elsewhere in this
gene cluster.
Based on our data, we propose a model in which the AFP enhancer
region is active early in hepatogenesis and required for AFP and
albumin activation during this time. The albumin enhancer can
activate the albumin promoter later during liver development, but
does not inﬂuence AFP promoter activity. The possibility that the
albumin enhancer becomes active after the albumin gene is turned on
is supported by transgenic studies in our lab (T. Ramesh and B.T.S.,
unpublished data) and albumin-Cre recombinase transgenic mice in
which Cre expression is ﬁrst detected later in fetal development
(Postic and Magnuson, 2000).
Elegant studies by Zaret and colleagues have shown that Foxa and
GATA factors bind the albumin enhancer in gut endoderm tissue prior
to albumin activation during hepatogenesis (Bossard and Zaret, 1998;
Gauldi et al., 1996). Binding of these pioneer factors is required for the
subsequent binding of other factors and albumin gene activation. Our
data showing a dramatic reduction in albumin expression in e10.5
liver in the absence of the AFP enhancer region indicate that the
albumin enhancer by itself is not sufﬁcient for albumin activation
during early stages of hepatogenesis. Whether the AFP enhancersdirectly inﬂuence the albumin promoter or inﬂuence the assembly of
factors, including Foxa and Gata 4, on the albumin enhancer will
require further study.
Our ChIP data provide direct evidence that enhancers are required
for the proper assembly of RNA polymerase on to a promoter during
mammalian development. Factors that bind the AFP and albumin
promoters have been identiﬁed and include HNF1, C/EBP and NFI.
Further studies can evaluate the binding of these factors in the
presence or absence of the AFP enhancers. Changes in chromatin can
also be analyzed. These studies will help elucidate the events involved
in promoter activation during development and in liver regeneration,
and the role enhancers play in these events.
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